Abemaciclib
|
|
|
- CAS-Nr.
- 1231929-97-7
- Englisch Name:
- Abemaciclib
- Synonyma:
- N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine;Abemaciclib (LY2835219);N-(5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine;CS-814;abecilee;Abemaciclib;Abemaciclib D7;Abemaciclib D10;ABEMACICLIB BASE;Abemaciclib, >=98%
- CBNumber:
- CB72624906
- Summenformel:
- C27H32F2N8
- Molgewicht:
- 506.59
- MOL-Datei:
- 1231929-97-7.mol
|
Abemaciclib Eigenschaften
- Siedepunkt:
- 689.3±65.0 °C(Predicted)
- Dichte
- 1.32±0.1 g/cm3(Predicted)
- storage temp.
- 4°C, protect from light
- Löslichkeit
- insoluble in H2O; ≥4.83 mg/mL in DMSO with gentle warming and ultrasonic; ≥6.34 mg/mL in EtOH with gentle warming
- Aggregatzustand
- solid
- pka
- 7.69±0.10(Predicted)
- InChIKey
- UZWDCWONPYILKI-UHFFFAOYSA-N
- SMILES
- C1(NC2=NC=C(CN3CCN(CC)CC3)C=C2)=NC=C(F)C(C2C=C3N(C(C)C)C(C)=NC3=C(F)C=2)=N1
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
Abemaciclib Chemische Eigenschaften,Einsatz,Produktion Methoden
Charakteristisch
Class: serine/threonine protein kinase
Treatment: Breast cancer
Oral bioavailability = 46%
Elimination half-life = 18 h
Protein binding = 95–98%
Biochem/physiol Actions
LY2835219 (abemaciclib) was identified via compound and biochemical screening by scientists at Eli Lilly and Company Research Laboratories and selected for its biological activity and highly selective inhibition of the complexes CDK4/ cyclin D1 (IC50 =2 nmol/L) and CDK6/cyclin D1 (IC50 =10 nmol/L), with no activity against other CDK/cyclin complexes or cell-cycle-related kinases within the nanomolar ranges, except for inhibition of CDK9 at IC50 at least five times higher. The compound was shown to act as a competitive inhibitor of the ATP-binding domain of the CDK4 and CDK6 and to be 14 times more potent against CDK4 than against CDK6. In comparison to palbociclib and ribociclib, abemaciclib shows higher selectivity for the complex CDK4/cyclin D1, with IC50 values five times lower than those of the two other compounds[1].
Enzyminhibitor
This oral cell cycle inhibitor (FWfree-base = 506.61 g/mol; FWmesylate-salt =
602.70 g/mol; CAS 1231930-82-7 (mesylate salt) ), also known as
LY2835219 and N-[5-[ (4-ethyl-1-piperazinyl) methyl]-2-pyridinyl]-5-
fluoro-4-[4-fluoro-2-methyl-1- (1-methylethyl) -1H-benzimidazol-6-yl]-2-
pyrimidinamine, targets the cyclin-dependent kinase CDK4, or cyclin D1
(IC50 = 2 nM) and CDK6, or cyclin D3 (IC50 = 6 nM), inhibiting
retinoblastoma (Rb) protein phosphorylation in early G1, thereby arresting
the cell cycle in the G1, suppressing DNA synthesis, and inhibiting cancer
cell growth. LY2835219 inhibits activation of AKT and ERK, but not
mTOR.
Abemaciclib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)-
4-Bromo-2,6-difluoroaniline
2-Bromopyridine-5-carbaldehyde
Piperazine, 1-[(6-broMo-3-pyridinyl)Methyl]-4-ethyl-
N-Isopropylacetamide
1H-BenziMidazole, 6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)-
1H-BenziMidazole, 4-fluoro-2-Methyl-1-(1-Methylethyl)-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)-
4-AMINO-3,5-DIFLUOROACETOPHENONE
5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine
6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole
1-Ethylpiperazin
2,6-Difluoranilin
Downstream Produkte
Abemaciclib Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 275)Lieferanten
- Abemaciclib, >=98%
- Abemaciclib
- abemaciclib(CDK 4/6 inhibitor)
- Bemaciclib(LY2835219, abemaciclib)
- CDK4/6 dual inhibitor
- LY 2835219 (free base)
- LY2835219 (free base)
- LY-2835219 (free base)
- Bemaciclib(LY2835219free base
- N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
- LY2835219(Abemaciclib)
- 2-Pyrimidinamine,N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-
- ethyl-1-(propan-2-yl)-1H-benzimidazol-6-yl]pyrimidin-2-amine
- LY2835219free base,Abemaciclib
- Abemaciclib free base
- ABEMACICLIB BASE
- Abemaciclib Mesylate (Verzenio)
- CS-814
- LY2835219;LY-2835219;LY 2835219;ABEMACICLIB;CDK4/6 DUAL INHIBITOR;LY-2835219 FREE BASE
- N-{5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl}-5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-1,3-benzodiazol-5-yl)pyrimidin-2-amine
- Abemaciclib D10
- Abemaciclib D7
- Abemaciclib (LY2835219)
- N-[5-[(4-Ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine
- N-(5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-yl)-5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazol-6-yl)pyrimidin-2-amine
- inhibit,LY-2835219,LY 2835219,Abemaciclib,Inhibitor,Cyclin dependent kinase,CDK
- 5-(4-ethylpiperazin-1-ylmethyl)pyridin-2-yl)-(5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzimidazol-5-yl)pyrimidin-2-yl)amine
- Abemaciclib Powder
- abecilee
- 1231929-97-7
- C27H32F2N8
- Inhibitors
- Pharmaceutical
- API
- 1231929-97-7
